Every 8-K that DENTSPLY SIRONA Inc. (XRAY) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow XRAY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XRAY filings page.
Dentsply Sirona Inc. corrected a technical SEC description tag in a prior report and announced financial results for the quarter ended June 30, 2026. Net sales were $898 million, down 4.1% year over year, while GAAP gross margin improved to 54.9%. Net income attributable to the company was $37 million, or $0.18 per diluted share, compared with a prior-year loss.
On a non-GAAP basis, adjusted EBITDA was $190 million with a 21.3% margin and adjusted EPS held at $0.52. Operating cash flow rose to $99 million and free cash flow to $55 million, supported by approximately $44 million of tariff refunds, and the company repurchased 1.3 million shares for about $12 million. Management reaffirmed 2026 guidance for net sales of $3.5–$3.6 billion and adjusted EPS of $1.40–$1.50.
Dentsply Sirona reported Q2 2026 net sales of $898 million, down 4.1% year over year, or 6.3% in constant currency. GAAP gross margin improved to 54.9% from 52.4%. Net income attributable to Dentsply Sirona was $37 million versus a prior-year loss of $45 million, with diluted EPS of $0.18 compared with a loss of $0.22.
On a non-GAAP basis, adjusted gross margin was 56.4%, adjusted EBITDA was $190 million with a 21.3% margin, and adjusted EPS was $0.52, unchanged from Q2 2025. Operating cash flow rose to $99 million, including about $44 million of tariff refunds, and free cash flow was $55 million. The company repurchased 1.3 million shares for approximately $12 million and ended June 30, 2026 with $239 million of cash and cash equivalents and long-term debt of $1,996 million. Management reiterated its 2026 outlook for net sales of $3.5–$3.6 billion and adjusted EPS of $1.40–$1.50, excluding tariff refunds from adjusted EPS guidance.
Dentsply Sirona is appointing John C. Fortson as Executive Vice President and Chief Financial Officer, effective July 20, 2026. He brings more than 25 years of leadership experience in finance, operations, and strategy across global manufacturing and industrial businesses, including prior CEO and CFO roles at Ingevity Corporation and senior finance roles at Kymera International and AAR Corp.
Under his offer letter, Fortson will receive a $780,000 annual base salary, a target annual bonus equal to 85% of base salary, and, beginning in 2027, annual equity awards targeted at $2.5 million. He is also entitled to a $500,000 sign-on cash payment and a $700,000 sign-on equity award split between premium stock options and restricted stock units, along with standard executive benefits, severance protections, and a non-competition agreement.
DENTSPLY SIRONA Inc. reported the results of its annual meeting of stockholders held on June 2, 2026. Stockholders elected twelve directors to serve until the next annual meeting or until successors are elected and qualified, with each nominee receiving more votes "For" than "Against."
Stockholders ratified the appointment of Deloitte & Touche LLP as independent registered public accountants for 2026, with 182,033,381 votes in favor. They also approved, on a non-binding advisory basis, the Company’s 2025 executive compensation. In addition, stockholders approved an amendment to the 2024 Omnibus Incentive Plan to increase the number of shares of common stock issuable under the plan by 15,000,000 shares.
Dentsply Sirona reported Q1 2026 results showing flat sales but weaker profitability while reiterating its full-year outlook. Net sales were $880 million versus $879 million a year ago, but GAAP results swung to a net loss of $10 million, or ($0.05) per share, from earnings of $20 million, or $0.10 per share.
On a non-GAAP basis, adjusted EPS was $0.27, down from $0.44, and adjusted EBITDA fell to $129 million with margin declining to 14.7% from 19.0%. Constant currency sales decreased 6.7% as growth in Wellspect Healthcare offset softer trends in Orthodontic and Implant Solutions and Essential Dental Solutions.
Operating cash flow improved to $40 million from $7 million, while free cash flow remained at negative $12 million. Cash and cash equivalents were $190 million and total equity was $1.3 billion as of March 31, 2026. The company highlighted the launch of its AI-enabled Smart View‑Detect diagnostic aid, new distribution agreements, and ongoing restructuring and capital allocation efforts, and maintained 2026 guidance for net sales of $3.5–$3.6 billion and adjusted EPS of $1.40–$1.50.
Dentsply Sirona reported Q4 2025 net sales of $961 million, up 6.2%, but a net loss of $146 million or ($0.74) per share, mainly from $144 million of goodwill and intangible impairments. Full-year 2025 net sales were $3.68 billion, down 3.0%, with a net loss of $598 million or ($3.00) per share.
On a non-GAAP basis, Q4 adjusted EPS was $0.27 and full-year adjusted EPS was $1.60. The company generated Q4 free cash flow of $60 million and full-year free cash flow of $104 million, ending 2025 with $326 million in cash and cash equivalents.
The Board approved a restructuring plan expected to create about $120 million in annualized cost savings, with $55–$65 million in non-recurring charges largely in 2026–2027. Dentsply Sirona also eliminated its quarterly dividend to redirect capital toward debt reduction and share repurchases. For 2026, it targets net sales of $3.5–$3.6 billion and adjusted EPS of $1.40–$1.50.
DENTSPLY SIRONA Inc. increased the size of its Board of Directors from 11 to 13 members and appointed James D. Forbes and Brian P. McKeon as new directors, effective February 27, 2026. They will serve until the director elections at the 2026 annual meeting of stockholders.
Forbes, a veteran healthcare investment banker with experience advising on more than $200 billion in financings and over $100 billion in M&A, will join the Compensation & Human Capital Committee. McKeon, a long-tenured public company CFO and director, will join the Audit and Finance Committee and the Science and Technology Committee.
The company highlights that their strategic and financial expertise is intended to support execution of its Return-to-Growth action plan and long-term value creation efforts. Long-serving director Willie A. Deese plans to retire from the Board and will not stand for re-election, and his decision is stated not to result from any disagreement with the company.
DENTSPLY SIRONA Inc. reported that it has entered into new non-exclusive distribution agreements with Patterson for the distribution of its dental equipment in the United States. The company disclosed this development through a current report and attached a press release as Exhibit 99.1 describing the arrangements. The disclosure is made under Regulation FD and is treated as information that is furnished rather than filed under the securities laws, which limits how it is incorporated into other company reports.
DENTSPLY SIRONA Inc. reported that its Board of Directors, following a recommendation from the Corporate Governance and Nominating Committee, increased the size of the Board from 10 to 11 members, effective January 10, 2026.
On the same date, the Board appointed Donald J. Zurbay as a director, with his term running until the election of directors at the 2026 annual meeting of stockholders. He will also serve on the Board’s Audit and Finance Committee. The company notes that he has no family relationships with existing leaders and no material related-party transactions requiring disclosure. He will receive the same compensation as other non-employee directors. The company furnished, but did not file, a press release about his appointment as Exhibit 99.1.
DENTSPLY SIRONA Inc. reported a leadership update, appointing Michael Pomeroy as interim Chief Financial Officer effective November 25, 2025. He will serve in this temporary role while the company searches for a permanent Chief Financial Officer.
During this period, President and Chief Executive Officer Daniel T. Scavilla will continue to act as the company’s principal financial officer in addition to his role as principal executive officer. Pomeroy brings extensive finance leadership experience across industrial, healthcare, consumer, and distribution businesses, including prior CFO roles at Icahn Automotive Group, Hollander-Keeco, and RGIS, and a recent interim CFO role at spinal devices company Highridge Medical.
DENTSPLY SIRONA filed an 8-K/A to disclose separation terms for former CFO Matthew E. Garth. The Separation Agreement provides separation payments totaling $1,200,000, paid in two installments of $600,000 each, plus $32,430 for twelve months of COBRA coverage and twelve months of outplacement services.
Mr. Garth remains eligible to earn a prorated portion (5/36ths) of his May 30, 2025 performance restricted share units based on actual achievement at the end of the performance period. All other unvested equity is forfeited and canceled. Payments and benefits are contingent on his execution and nonrevocation of a release of claims and compliance with post-termination restrictive covenants.
DENTSPLY SIRONA (XRAY) furnished an 8-K announcing it issued a press release with financial results for the third fiscal quarter ended September 30, 2025. The press release is provided as Exhibit 99.1 under Item 2.02. The company notes this information is being furnished, not filed, under the Exchange Act, and therefore is not subject to Section 18 liabilities or incorporation by reference unless specifically referenced.
DENTSPLY SIRONA (XRAY) announced a leadership change. On October 31, 2025, the company determined that Matthew E. Garth will no longer serve as Executive Vice President and Chief Financial Officer, effective November 5, 2025. The company has begun a search for its next CFO. The filing states Mr. Garth’s departure was not due to any disagreement regarding financial statements, internal controls, or operations.
Effective upon Mr. Garth’s departure, Daniel T. Scavilla, the company’s President and CEO and a director, was appointed as interim principal financial officer for SEC reporting. The company noted no new compensatory arrangements for Mr. Scavilla related to these additional responsibilities, and no related‑party relationships were disclosed.
DENTSPLY SIRONA announced that the SEC’s Division of Enforcement has concluded its investigation and does not intend to recommend any enforcement action against the company. The inquiry, initiated by the SEC in connection with an internal review led by the Audit and Finance Committee into certain financial reporting matters raised by employees, began in May 2022 and closed on October 14, 2025. The company had voluntarily contacted the SEC and fully cooperated throughout.
The closure removes a regulatory overhang tied to past financial reporting questions and reflects the regulator’s decision not to pursue action. Management characterized the outcome as a significant and favorable development.
DENTSPLY SIRONA Inc. announced that Richard C. Rosenzweig, Executive Vice President, Corporate Development, General Counsel and Secretary, will step down from that role by mutual agreement effective October 3, 2025. He will serve as a non-executive Special Legal Advisor through a Separation Date no later than March 4, 2026 to transition responsibilities. Under a Transition and Separation Agreement dated October 2, 2025, he is eligible for severance under prior agreements and will receive a monthly fixed fee of $30,000 while Special Legal Advisor; if terminated early without Cause, that amount is payable as if he served through March 4, 2026. After the Separation Date, the Company will engage him as an independent contractor for one year at $20,000 per month. Receipt of these payments is generally contingent on execution of a release and compliance with post-termination covenants. The Transition and Separation Agreement is filed as Exhibit 10.1.
DENTSPLY SIRONA Inc. approved a one-time retention equity award to certain executives, including named executive officer Tony Johnson, Senior Vice President and Chief Supply Chain Officer. The award is a stock option grant with a grant date fair value of $2,000,000 awarded to Mr. Johnson to recognize his performance during recent CEO and CFO transitions and to incentivize retention through the next three years.
The options are expected to be granted on the second trading day after the company files its quarterly report for the fiscal quarter ended September 30, 2025, will cliff-vest on the third anniversary of the grant date provided continuous employment, and will expire on the tenth anniversary. Half of the options will have an exercise price equal to the fair market value on the grant date and half will have an exercise price equal to 110% of that value.
DENTSPLY SIRONA Inc. announced on September 8, 2025 that it completed its previously disclosed review of strategic alternatives for its Wellspect Healthcare business and the Board determined that Wellspect will remain within the Company’s portfolio. The Company furnished a related press release as Exhibit 99.1 to this Current Report on Form 8-K. The filing notes the exhibit is furnished (not "filed") and therefore is not incorporated by reference into other Securities Act or Exchange Act filings absent specific reference. No financial statements, transaction terms, or forward-looking guidance are included in the provided text.